UK markets closed

G1 Therapeutics, Inc. (GTHX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.9900+0.1300 (+3.37%)
At close: 04:00PM EDT
3.9899 -0.00 (-0.00%)
After hours: 05:01PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.8600
Open3.8500
Bid3.9700 x 200
Ask4.0200 x 100
Day's range3.8400 - 4.0450
52-week range1.0800 - 5.0000
Volume441,095
Avg. volume1,282,777
Market cap208.276M
Beta (5Y monthly)1.70
PE ratio (TTM)N/A
EPS (TTM)-0.9300
Earnings date01 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.50
  • Simply Wall St.

    G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profit

    We feel now is a pretty good time to analyse G1 Therapeutics, Inc.'s ( NASDAQ:GTHX ) business as it appears the company...

  • GlobeNewswire

    G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024

    RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on Wednesday May 1, 2024, at 8:30 a.m. ET. To register for the event and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 1

  • GlobeNewswire

    G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 8:45 AM ET. The webcast of the event will be accessible on the Events & Presentations page of https://www.g1therapeutics.com/. About G1 TherapeuticsG1 Therapeutics, In